Medical Doctor Program year 2020 Reported 2019–2020 Source: CMS Open Payments, 2026 publication

Berne Bahnson

Psychiatry Sioux Falls, SD Medical Doctor

NPI 1871565499 CMS profile 39839

4400 W 69Th St, Ste 500, Sioux Falls, SD 57108

Open in the dashboard

General payments

$949

77 records reported · program years 2019–2020

Research payments

$0

Paid to them · None reported · program years 2019–2020

Ownership & investment interest

$0

None reported

Through program year 2020, Berne Bahnson of Sioux Falls, SD is reported in the CMS Open Payments database as having received $949 across 77 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 70th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2020 General $176 12
2019 General $773 65

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Berne Bahnson
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Berne Bahnson were reported at $0. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Berne Bahnson Psychiatry median Middle half National median
2019 $773 $184 $59–$605 $163
2020 $176 $119 $36–$372 $114
2021 $0 $143 $43–$576 $132
2022 $0 $153 $50–$590 $149
2023 $0 $170 $56–$651 $160
2024 $0 $179 $57–$673 $164
2025 $0 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2020
  1. Shire North American Group Inc $227 22 payments
  2. Otsuka America Pharmaceutical, Inc. $172 12 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $142 15 payments
  4. ACADIA Pharmaceuticals Inc $61 4 payments
  5. Lundbeck LLC $58 4 payments
  6. Neos Therapeutics, LP $56 3 payments
  7. Avanir Pharmaceuticals, Inc. $39 3 payments
  8. Merck Sharp & Dohme Corporation $39 3 payments
  9. Sunovion Pharmaceuticals Inc. $38 2 payments
  10. Janssen Pharmaceuticals, Inc $35 2 payments
  11. Other $83 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2020
  1. Food and Beverage $949 77 payments
Products named General payments · program years 2019–2020
  1. VYVANSE $238 23 payments
  2. Trintellix $108 12 payments
  3. REXULTI $95 7 payments
  4. ABILIFY MAINTENA $77 5 payments
  5. NUPLAZID $61 4 payments
  6. COTEMPLA XR-ODT $56 3 payments
  7. Adzenys XR-ODT $56 3 payments
  8. NUEDEXTA $39 3 payments
  9. BELSOMRA $39 3 payments
  10. LATUDA $38 2 payments
  11. Other $272 20 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 69 drugs

Part D claims

6,084

Median for Psychiatry: 574

Drug cost

$617,568

Median for Psychiatry: $27,624

Branded share of claims

21.6%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ingrezza Valbenazine Tosylate Brand 23 $173,625
Invega Sustenna Paliperidone Palmitate Brand 33 $79,831
Aristada Aripiprazole Lauroxil Brand 26 $76,525
Rexulti Brexpiprazole Brand 34 $52,160
Vraylar Cariprazine Hcl Brand 26 $39,490
Vyvanse Lisdexamfetamine Dimesylate Brand 97 $35,889
Fanapt Iloperidone Brand 12 $21,117
Lurasidone Hcl Generic 60 $18,297
Belsomra Suvorexant Brand 43 $17,942
Lisdexamfetamine Dimesylate Generic 45 $10,058

The 10 drugs with the highest cost, of 69 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$32,192

Medicare's payments for the services billed

Medicare patients

176

Average age 65

Services billed

438

111 women, 65 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 61%
High blood pressure 56%
Arthritis 38%
Diabetes 21%
Chronic kidney disease 20%
Osteoporosis 19%
Alzheimer's or dementia 15%
Ischemic heart disease 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

77 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2020

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record